

Robin Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8005339/publications.pdf>

Version: 2024-02-01

9
papers

486
citations

1163117
8
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

776
citing authors

#	ARTICLE	IF	CITATIONS
1	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
2	MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1666-1671.	1.1	115
3	Immunophenotype and Response to Immunotherapy of <i>RET</i> -Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	73
4	<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	7.0	35
5	Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	26
6	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 655-660.	1.1	25
7	MET inhibitor resistance in patients with MET exon 14-altered lung cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 9006-9006.	1.6	24
8	CNS Metastases in Patients With MET Exon 14-altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	3.0	14
9	Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. <i>Lung Cancer</i> , 2021, 162, 23-28.	2.0	9